Dianthus Therapeutics — Q3 2026 Earnings Summary

Dianthus Therapeutics reported a net loss of $46.6 million for the third quarter ended September 30, 2026, with research and development expenses rising to $45.6 million. The company maintains approximately $1.2 billion in cash and investments, projecting a runway into 2030. Clinical progress includes top-line results for the Phase 2 MoMeNtum trial of claseprubart in multifocal motor neuropathy expected in December 2026, while Phase 3 trials for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy are on track for 2028. Additionally, the investigational bifunctional fusion proteins DNTH212 and DNTH312 are advancing, with DNTH312 expected to be Phase 1 ready by the end of 2027.